Brief: AB Science: Case Report From Initial Phase I/II Study Evaluating Ab8939

AB Science SA

13/03/2023 17:29

March 13 (Reuters) - Ab Science Sa  ABS.PA :
    * AB SCIENCE REPORTS A FIRST COMPLETE BONE MARROW RESPONSE
IN A
RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA PATIENT FROM THE VERY
LOW DOSE ARM OF ITS AB8939 PHASE I/II CLINICAL TRIAL (AB18001)
    * TODAY ANNOUNCES A CASE REPORT FROM THE INITIAL STAGE OF
ITS
PHASE I/II STUDY (AB18001)
    * ONE MONTH AFTER FIRST TREATMENT CYCLE THERE WAS DRASTIC
REDUCTION IN BONE MARROW BLAST CELLS (I.E., LEUKEMIA CELLS),
FROM A PRETREATMENT LEVEL OF 55% TO 5% (I.E., A MORPHOLOGIC
LEUKEMIA FREE STATE)
    * THIS RESPONSE WAS ACHIEVED AT A VERY LOW DOSE OF AB8939,
CORRESPONDING TO SECOND STEP OF DOSE INCREMENT (OUT OF 13
POTENTIAL STEPS) IN PHASE I.
    * PATIENT ALSO SHOWED EXCELLENT TOLERANCE TO AB8939, HAVING
EXPERIENCED NO TREATMENT-RELATED TOXICITIES.
    * ONE MONTH AFTER SECOND TREATMENT CYCLE OF THREE
CONSECUTIVE DAYS
AT THIS DOSE, A GOOD RESPONSE HAS BEEN MAINTAINED WITH BONE
MARROW BLASTS BEING AT 10% (CORRESPONDING TO A 5-FOLD REDUCTION
RELATIVE TO BASELINE).
    * THERE HAVE BEEN NO SIGNS OF MODERATE, SEVERE OR SERIOUS
TOXICITY
AND APPROXIMATELY 50% OF PATIENTS HAVE REQUESTED FURTHER
TREATMENT CYCLES OF AB8939 AFTER FIRST CYCLE OF TREATMENT AND A
MEASUREMENT AT DAY 28.

Source text for Eikon:  ID:nGNE2dmXqt 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))